GLATIRAMER ACETATE VERSUS INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION: A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS

被引：0
|
作者：
Castelli-Haley, J. [1 ]
Oleen-Burkey, M. [1 ]
Lage, M. J. [2 ]
Johnson, K. [3 ]
机构：
[1] Teva Neurosci, Kansas City, MO USA
[2] Hlth Metr Outcomes Res, Groton, CT USA
[3] Univ Maryland, Baltimore, MD 21201 USA
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66967-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A601 / A601
页数：1
相关论文
共 50 条
  • [1] Glatiramer acetate versus interferon beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients
    Castelli-Haley, Jane
    Oleen-Burkey, Merry-Kay A.
    Lage, Maureen J.
    Johnson, Kenneth P.
    ADVANCES IN THERAPY, 2008, 25 (07) : 658 - 673
  • [2] Glatiramer acetate versus interferon Beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients
    Jane Castelli-Haley
    MerryKay A. Oleen-Burkey
    Maureen J. Lage
    Kenneth P. Johnson
    Advances in Therapy, 2008, 25 (8) : 830 - 830
  • [3] Glatiramer acetate versus interferon beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients
    Jane Castelli-Haley
    Merry-Kay A. Oleen-Burkey
    Maureen J. Lage
    Kenneth P. Johnson
    Advances in Therapy, 2008, 25 : 658 - 673
  • [4] GLATIRAMER ACETATE VERSUS INTERFERON BETA-1B FOR SUBCUTANEOUS ADMINISTRATION: A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS
    Castelli-Haley, J.
    Oleen-Burkey, M.
    Lage, M. J.
    Johnson, K.
    VALUE IN HEALTH, 2008, 11 (06) : A600 - A600
  • [5] Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis
    Jane Castelli-Haley
    MerriKay A. Oleen-Burkey
    Maureen J. Lage
    Kenneth P. Johnson
    Advances in Therapy, 2009, 26 : 552 - 562
  • [6] Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis
    Castelli-Haley, Jane
    Oleen-Burkey, MerriKay A.
    Lage, Maureen J.
    Johnson, Kenneth P.
    ADVANCES IN THERAPY, 2009, 26 (05) : 552 - 562
  • [7] Real-world outcomes in patients with relapsing forms of multiple sclerosis treated with intramuscular interferon beta-1a or peginterferon beta-1a
    Salter, A.
    Lancia, S.
    Cutter, G.
    Fox, R.
    Marrie, R. A.
    Avila, R.
    Vignos, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 187 - 187
  • [8] Real World Relapse Rates of Glatiramer Acetate Patients Switching to Fingolimod or Interferon Beta-1a Versus Remaining on Glatiramer Acetate
    Li, Yunfeng
    Nazareth, Tara
    Zhou, Huanxue
    Johnson, Kristen
    Ko, John
    Hawker, Kathleen
    Herrera, Vivian
    Sasane, Rahul
    NEUROLOGY, 2016, 86
  • [9] Real world relapse rates of glatiramer acetate patients switching to fingolimod or interferon beta-1a versus remaining on glatiramer acetate
    Li, Y.
    Nazareth, T.
    Zhou, H.
    Ko, J. J.
    Johnson, K. M.
    Hawker, K.
    Herrera, V.
    Sasane, R.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 771 - 771
  • [10] Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports
    Rastkar, Mohsen
    Ghajarzadeh, Mahsa
    Sahraian, Mohammad Ali
    CURRENT JOURNAL OF NEUROLOGY, 2023, 22 (02): : 115 - 136
12345